Healx announces agreement with Sanofi to seek new rare disease ...
1 day ago · CAMBRIDGE, England, November 13, 2024--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...
Healx announces agreement with Sanofi to seek new rare disease ...
2 days ago · Cambridge, UK, November 13, 2024 –Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing ...
Healx announces agreement with Sanofi to seek new rare disease ...
1 day ago · Healx will analyze proprietary Sanofi compound data using Healx’s AI-driven drug discovery platform to generate therapeutic rationale. CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform.
AI Collaboration Between Sanofi and Healx Will Target Novel …
1 day ago · November 13, 2024. Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify ...
Healx and Sanofi unite to probe new disease indications
1 day ago · In the latest development, it will use a Sanofi compound to identify the new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. Financial terms of the partnership are not disclosed.
Healx Announces Agreement with Sanofi to Seek New Rare …
1 day ago · Healx announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx's AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. Financial terms of the partnership are not disclosed.
Healx Enters Agreement to Use Its AI Platform to Discover New …
2 days ago · Healx has built a suite of technologies to rapidly identify and progress new therapies for some of the 95 percent of rare diseases currently without an approved treatment. Healx will use its drug discovery and development expertise to provide Sanofi with an AI-driven therapeutic rationale to support the compound’s future development.
Healx raises $47m Series C to progress AI-driven rare disease …
Cambridge-based Healx, an AI-enabled clinical-stage biotech company specialising in rare diseases, has raised a $47 million Series C round to advance its lead program through trials.
Healx receives FDA clearance for Phase II neurofibroma trial
Aug 2, 2024 · Healx has secured the US Food and Drug Administration (FDA) clearance for an investigational new drug application (IND) to commence a Phase II clinical trial of HLX-1502, targeting adults with neurofibromatosis Type 1 (NF1) and inoperable plexiform neurofibroma.
How third-generation drug discovery is transforming rare disease ...
With its Healnet platform, Healx pairs cutting-edge AI with industry-leading drug discovery and rare disease expertise to identify new uses for known compounds.
- Some results have been removed